StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca calquence (acalabrutinib) — Europe YoY CER (%) (%)

Form 6-K / 20-F Product Sales Table

QuarterlyAnnual
Latest, Q2 2026
9.0%
Period ended Jun 30, 2026
Change on a year earlier
-5.0 pts
14.0% in Q2 2025
History
13 quarters
Since Q2 2023
Sources
13
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCalquence (acalabrutinib) — Europe YoY CER (%) (%)Year on yearSource
Q2 2026Jun 30, 20269.0%-5.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202613.0%-2.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202520.0%+2.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202512.0%-20.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202514.0%-29.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202515.0%-24.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202418.0%-34.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202432.0%-22.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202443.0%-35.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202439.0%–Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202352.0%–Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202354.0%–Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202378.0%–Form 6-K FY2023Q2 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Calquence (acalabrutinib) — Europe YoY CER (%) (%), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_calquence_eu_cer_yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.